ECCO 2025

The importance of endoscopic surveillance – current…

Surgical approaches in IBD – all questions solved?

Personalized dosing of infliximab in moderate to severe…

Eating is part of life – and of special therapeutic…

Comparative efficacy between biologics in UC – the need…

The perfect dosing of our drugs – data on ustekinumab…

New UC-kids on the block: a IL7 receptor antagonist &…

Combination therapies – on the way to the holy grail?

What is the best treatment goal for moderate to severe…

Urgency – what is hen and what is egg?

Update on fistulizing disease

Comparative efficacy and safety – do we need to…

Subcutaneous induction with guselkumab in CD is…

Early CD treatment with vedolizumab

Subcutaneous therapy with guselkumab for Crohn's…

The need for early treatment in Crohn’s disease – a…

Dose escalation of vedolizumab in CD is not effective

Kono-S anastomosis is not superior to side-to-side…

Rola wczesnej terapii choroby Leśniowskiego-Crohna –…

La anastomosis Kono-S no es superior a la anastomosis…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

Obefazimod maintenance treatment: a new approach

First combination of upadacitinib and vedolizumab in…

Personalized dosing in acute UC

How to treat UC patients after failure of a s.c.…

Appendectomy – a good option for UC

Long-term efficacy and safety of a lower obefazimod…

Obefazimod in der Erhaltung: Neuer Ansatz

Long-term efficacy and safety of a lower obefazimod…

Erste Kombination von Upadacitinib und Vedolizumab bei…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

Appendektomie – eine gute Option bei Colitis Ulcerosa

Lusvertikimab – a first-in-class IL7 receptor…

A new class of drugs: anti-TL1A antibodies

s.c.? i.v.? Just swallow it! News from the oral…

SOR102 – a novel oral bispecific antibody in patients…

New mode of action for treating UC

Eine neue Substanzklassen: Anti-TL1A Antikörper

SOR102 – un nuovo anticorpo bispecifico orale in…

Nouveau mode d'action pour le traitement de la RCH

s.c.? i.v.? Einfach schlucken! Neues vom oralen…

טיפולים חדשים- fast forward לעתיד

Minimal Residual Disease: a new treatment goal in IBD?

Association between histologic response and…

What is the best treatment goal for moderate to severe…

Mirikizumab demonstrates rapid improvements in bowel…

Comprehensive approach necessary to treat our patients…

גישה כוללנית הכרחית לטיפול בחולים בדרך המיטבית

Was ist der beste Therapieendpunkt bei moderater bis…

Mirikizumab demonstrates rapid improvements in bowel…

Definiendo la curación radiológica en enfermedad de…

Tasty&Healthy diet is better tolerated than exclusive…

A low emulsifier diet is a treatment for moderate to…

Fibre consumption and the risk of developing CD

Spożycie błonnika a ryzyko zachorowania na chorobę…

Comparative efficacy of infliximab and vedolizumab…

PODIUM: effectiveness & safety of 2nd line vedolizumab…

ASTRO study established the efficacy of guselkumab…

Etrasimod improves clinical, endoscopic and histologic…

Efficacia e sicurezza di una terapia combinata avanzata…

El estudio ASTRO demuestra la eficacia de Guselkumab en…

Eficacia comparativa de infliximab vs. vedolizumab tras…

Second line treatment for perianal Crohn's disease

Dose escalation of primary non-responders is not…

Effectiveness & safety of advanced combination therapy…

Optimizing biologics in CD – is it relevant for all?

אופטימיזציה של תכשירים ביולוגים במחלת קרוהן-האם מתאים…

Mancato aumento dei livelli terapeutici di IFX nella…

Zweitlinie bei Crohn-Fisteln

Risk of IMID associated with anti-TNF and ustekinumab…

Czynniki psychologicne a ryzyko zaostrzenia IBD

How to detect preneoplastic lesions by coloscopy

αvβ6 – ein neuer Biomarker zur Prädiktion, Staging und…

HLA typing – tailoring treatment a step forward?

Identificazione di clonotipi specifici nella malattia…